Number of samples analyzed and distribution of samples in each WHO 2008 MDS subtype
| . | Samples . | |
|---|---|---|
| Samples analyzed for TED | 205 | |
| Control samples | 16 | |
| Samples with myeloid malignancies (113 unique patients) | 221 | |
| Samples with TED | 149 | |
| Adequate samples but NoTED | 56 | |
| TED (%) | NoTED (%) | |
| MDS | ||
| RCUD | 1 (100) | 0 (0) |
| RA | 11 (73) | 4 (27) |
| RCMD | 73 (70) | 32 (30) |
| RARS | 21 (91) | 2 (9) |
| RAEB-1 | 16 (76) | 5 (24) |
| RAEB-2 | 21 (68) | 10 (32) |
| MDS/MPN | ||
| RARS-T | 6 (66) | 3 (34) |
| Total | 149 | 56 |
| . | Samples . | |
|---|---|---|
| Samples analyzed for TED | 205 | |
| Control samples | 16 | |
| Samples with myeloid malignancies (113 unique patients) | 221 | |
| Samples with TED | 149 | |
| Adequate samples but NoTED | 56 | |
| TED (%) | NoTED (%) | |
| MDS | ||
| RCUD | 1 (100) | 0 (0) |
| RA | 11 (73) | 4 (27) |
| RCMD | 73 (70) | 32 (30) |
| RARS | 21 (91) | 2 (9) |
| RAEB-1 | 16 (76) | 5 (24) |
| RAEB-2 | 21 (68) | 10 (32) |
| MDS/MPN | ||
| RARS-T | 6 (66) | 3 (34) |
| Total | 149 | 56 |
RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia.